9Graham DJ,Ouellet-Hellstrom R,,MaCurdy TE ,et al. Risk of acutemyocardial infarction,stroke,,heart failure,and death in elderly medicare patients treated with rosightazone or pioglita- zone. JAMA,2010,304:411-418.
10Woodcock J,Sharfstein JM,Hamburg M. Regulatory action on rosiglitazone by the US Food and Drug Admimistration. N En- gl J Med,2010,363(16):1489-1491.
5Day CP, James OF. Steatohepatitis : a tale of two "hit?" Gastroenterology, 1998,114 (4) : 842-845.
6Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology ,2002,35 (2) :373-379.
7Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 2003, 38 ( 4 ) : 1008-1017.
8Kawaguchi K, Sakaida I, Tsuchiya M, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient 1-amino acid-defined diet. Biochem Biophys Res Common,2004,315 ( 1 ) :187-195.
10Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol, 2007, 47: 135-141.
